7X5-32719-20979
2 vaccinations
6 coded responses
22 check-ins
6 free-text entries
1 call case
- Sex
- Male
- Age at first dose
- 46-50
- ZIP prefix
- 891 / NV
- Registered
- 2021-11-03
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-11-03
Registered in v-safe
-
2021-11-03
Dose 1 — Pfizer-BioNTech
- 2021-11-03
- 2021-11-05
- 2021-11-06
- 2021-11-07
-
2021-11-09
Survey response — days 1–6 daily, dose 1MedDRA: Body temperature decreased, Unevaluable event — Feeling: Fair · Headache, Fatigue or tiredness, Nausea · Be unable to work or attend schoolFree text: May just be other seasonal symptoms; BP 112/70; PulseOx 96; temp 97.8°FMedDRA releases: 2024-11 · check-in free text available
- 2021-11-10
- 2021-11-17
-
2021-11-24
Dose 2 — Pfizer-BioNTech
- 2021-11-24
-
2021-11-25
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fatigue or tirednessAdult check-in
-
2021-11-26
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Headache, Fatigue or tirednessAdult check-in
-
2021-11-27
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Headache, Fatigue or tirednessAdult check-in
-
2021-11-28
Health check-in — days 1–6 daily, dose 2Feeling: Poor · Headache, Fatigue or tiredness, Nausea · Be unable to do your normal daily activitiesAdult check-in
-
2021-11-29
Health check-in — days 1–6 daily, dose 2Feeling: Poor · Headache, Fatigue or tiredness, Nausea · Be unable to do your normal daily activitiesAdult check-in
- 2021-12-01
- 2021-12-08
-
2021-12-15
Survey response — day 21, dose 2MedDRA: Dizziness, Fatigue, Myalgia, Nausea — Feeling: Fair · Be unable to do your normal daily activitiesFree text: Continued fatigue, possibly unrelated symptoms to seasonal allergies and possible mild head cold. Dizziness, nausea, upper thoracic muscle pain around ribcage. Blood pressure is good (118/70) pulse OX good at 96 (2250 ft MSL). Taste and smell intactMedDRA releases: 2024-11 · check-in free text available
- 2021-12-22
- 2021-12-29
-
2022-01-05
Survey response — day 42, dose 2MedDRA: Heart rate increased, Heart rate variability decreased, Joint injury — Feeling: Fair · Be unable to do your normal daily activitiesFree text: Possible seasonal cold/flu. Temperature normal, pulse Oxygen normal, blood pressure normal (119/70), slight raise in RHR and a low HRV (11). Knee injury to patella (new).MedDRA releases: 2024-11 · check-in free text available
-
2022-02-23
Survey response — 3 months, dose 2MedDRA: COVID-19 — Feeling: Fair · Be unable to do your normal daily activitiesFree text: Ormicron, asymptomatic.MedDRA releases: 2024-11 · check-in free text available
-
2022-05-25
Survey response — 6 months, dose 2MedDRA: Dyspnoea, Hypoxia, Lactic acidosis, Pneumonia, Sepsis — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visit, Emergency room or emergency department visit, HospitalizationFree text: Pneumonia, severe hypoxia, severe sepsis, dyspnea and lactic acidosis.MedDRA releases: 2024-11 · check-in free text available
-
2022-05-25
Report sent to call center — 6 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · Emergency room or emergency department visit · Hospitalization · 1 call case(s)
- 2022-05-26
-
2022-11-24
Survey response — 12 months, dose 2MedDRA: Interstitial lung disease, Oxygen saturation decreased — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Diagnosis of probable ILD with issues in SP02 decline when transioning altitude about 2800+ft MSL.MedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-11-03 | Pfizer-BioNTech | No |
| 2 | 2021-11-24 | Pfizer-BioNTech | No |
Call center
1 call center case
1 unsuccessful
Free text
Release 10 — days 1–6 daily, dose 1
Systemic reaction (other): May just be other seasonal symptoms; BP 112/70; PulseOx 96; temp 97.8°F
Release 10 — day 21, dose 2
Symptoms: Continued fatigue, possibly unrelated symptoms to seasonal allergies and possible mild head cold. Dizziness, nausea, upper thoracic muscle pain around ribcage. Blood pressure is good (118/70) pulse OX good at 96 (2250 ft MSL). Taste and smell intact cut off by CDC
Release 10 — day 42, dose 2
Symptoms: Possible seasonal cold/flu. Temperature normal, pulse Oxygen normal, blood pressure normal (119/70), slight raise in RHR and a low HRV (11). Knee injury to patella (new).
Release 11 — 3 months, dose 2
Symptoms: Ormicron, asymptomatic.
Release 11 — 6 months, dose 2
Symptoms: Pneumonia, severe hypoxia, severe sepsis, dyspnea and lactic acidosis.
Release 12 — 12 months, dose 2
Symptoms: Diagnosis of probable ILD with issues in SP02 decline when transioning altitude about 2800+ft MSL.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | COVID-19 | · | · | ✓ |
| SD | Dizziness | · | · | ✓ |
| SD | Dyspnoea | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Heart rate increased | · | · | ✓ |
| SD | Heart rate variability decreased | · | · | ✓ |
| SD | Hypoxia | · | · | ✓ |
| SD | Interstitial lung disease | · | · | ✓ |
| SD | Joint injury | · | · | ✓ |
| SD | Lactic acidosis | · | · | ✓ |
| SD | Myalgia | · | · | ✓ |
| SD | Nausea | · | · | ✓ |
| SD | Oxygen saturation decreased | · | · | ✓ |
| SD | Pneumonia | · | · | ✓ |
| SD | Sepsis | · | · | ✓ |
| SRO | Body temperature decreased | · | · | ✓ |
| SRO | Unevaluable event | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release